In a highly international research environment, cutting-edge technologies are being created and deployed to accelerate the drug discovery process, helping to develop new and ever more effective treatments.
A leader in novel technologies and therapies
Belgium is a world leader in the development of new medicines, therapies, and applications - especially in the context of ATMPs, mRNA technology, next-generation vaccines, plasmaproteins, and antibodies.
The first-ever cellular product to complete its full developmental cycle as an ATMP, under the guidance of the EMA, was developed in Belgium.
Belgium is a global powerhouse in vaccines with extensive capabilities in research, development and manufacturing.
Plasma proteins & antibodies
As the first nation to discover nanobodies, Belgium has been producing plasma and recombinant proteins for years.
Unrivalled R&D incentives
A generous tax incentive package includes:
- 80% deduction on the withholding tax for R&D employees.
- Up to 85% deduction on innovation income tax.
- Public subsidies and refundable cash advances.
- Tax deductions for investments in patents and R&D.
Want to know more?
Belgium has big plans for the future. This is how we intend to make them happen.
Strengthen an already highly competitive position as a talent, business, and innovation hothouse.
Harness the potential of Belgium's rich health data sources to improve patient outcomes and public health.
Encourage close collaboration between businesses, universities, hospitals, and public-private partnerships.
Adopt a truly end-to-end approach across the entire biotech value chain, from early research to patient access.
Take innovative platforms such as cell therapy, gene therapy, digital therapeutics, and mRNA to the next level.